DDInter1484 DDInter1676
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan
Plicamycin may lead to a major life threatening interaction when taken with Regorafenib